AKA-349
Dotinurad

Cat. No.

AKA-349

CAS No.

1285572-51-1

MF

C14H9Cl2NO4S

MW

358.2

Dotinurad is a potent and selective inhibitor of urate reabsorption.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service
Need help? Our team of experienced experts is here for you with full support.
86-28-85159085
info@aktin.com
Inquiry
Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Dotinurad
CAS No.
1285572-51-1
MF
C14H9Cl2NO4S
MW
358.2
Specification
98%
Research Area
Solute Carrier Family 22 Member 12
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Description
Dotinurad is a potent and selective inhibitor of urate reabsorption.
Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg
Availability: DMF preparation & filing in progress
Documents
Can't find the right version? Our team of experienced experts is here for you with full support. 
Contact Us
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J Pharmacol Exp Ther. 2019;371(1):162-70.
Related Products
AKA-372
Dipexion™ Fmoc-Val-Ser(psi(Me,Me)pro)-OH

CAS No.:186023-49-4

MF:C26H30N2O6

View Details
AKA-371
Dipexion™ Fmoc-Gly-Ser(psi(Me,Me)pro)-OH

CAS No.:1095952-22-9

MF:C23H24N2O6

View Details
AKA-370
Oxymatrine

CAS No.:16837-52-8

MF:C15H24N2O2

View Details
AKA-369
Matrine

CAS No.:519-02-8

MF:C15H24N2O

View Details
AKA-367
Dipexion™ Fmoc-Leu-Ser[PSI(Me,Me)Pro]-OH

CAS No.:339531-50-9

MF:C27H32N2O6

View Details
AKA-366
Dipexion™ Fmoc-Ser(tBu)-Thr[PSI(Me,Me)Pro]-OH

CAS No.:1266350-99-5

MF:C29H36N2O7

View Details
AKA-365
Dipexion™ Fmoc-Glu(OtBu)-Thr[PSI(Me,Me)Pro]-OH

CAS No.:957780-56-2

MF:C31H38N2O8

View Details
AKA-363
Dipexion™ Fmoc-Thr(tBu)-Ser[PSI(Me,Me)Pro]-OH

CAS No.:1425938-63-1

MF:C29H36N2O7

View Details
* Some statements have not been evaluated by national authorities.
* Some products are not intended to diagnose, treat, cure, or prevent any disease.
* For literature supporting, please contact us directly.
Cart
TotalProducts
Request Quote
  • China
  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Brunei
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Central African Republic
  • Chad
  • Chile
  • Colombia
  • Comoros
  • Congo (Brazzaville)
  • Congo (Kinshasa)
  • Cook Islands
  • Costa Rica
  • Côte d'Ivoire
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • East Timor (Timor-Leste)
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Eswatini
  • Ethiopia
  • Fiji
  • Finland
  • France
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Greece
  • Grenada
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • South Korea
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Morocco
  • Mozambique
  • Myanmar (Burma)
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • North Macedonia
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Rwanda
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • Spain
  • Sri Lanka
  • Sudan
  • South Sudan
  • Suriname
  • Sweden
  • Switzerland
  • Syria
  • Tajikistan
  • Tanzania
  • Thailand
  • Togo
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates (UAE)
  • United Kingdom (UK)
  • United States (US)
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Vatican City
  • Venezuela
  • Vietnam
  • Yemen
  • Zambia
  • Zimbabwe
  • Beijing-Beijing
  • Tianjin-Tianjin
  • Hebei-Shijiazhuang
  • Shanxi-Taiyuan
  • Inner Mongolia-Hohhot
  • Liaoning-Shenyang
  • Jilin-Changchun
  • Heilongjiang-Harbin
  • Shanghai-Shanghai
  • Jiangsu-Nanjing
  • Zhejiang-Hangzhou
  • Anhui-Hefei
  • Fujian-Fuzhou
  • Jiangxi-Nanchang
  • Shandong-Jinan
  • Henan-Zhengzhou
  • Hubei-Wuhan
  • Hunan-Changsha
  • Guangdong-Guangzhou
  • Guangxi-Nanning
  • Hainan-Haikou
  • Chongqing-Chongqing
  • Sichuan-Chengdu
  • Guizhou-Guiyang
  • Yunnan-Kunming
  • Tibet-Lhasa
  • Shaanxi-Xi'an
  • Gansu-Lanzhou
  • Qinghai-Xining
  • Ningxia-Yinchuan
  • Xinjiang-Urumqi
  • Hong Kong-Hong Kong
  • Macao-Macao
  • Taiwan-Taipei